STRYKER 864952 - eine der besten Medizintechnikaktien (Seite 7)

[1435905]

Bin gespannt was aus dieser Meldung wird, die um Weihnachten die Runde machte:


Stryker Plans Takeover Bid For Smith & Nephew

Orthopedics devices maker Stryker Corp. (SYK) is planning a takeover bid for UK-based medical device maker Smith & Nephew plc (SNN, SN.L) in the coming weeks, Bloomberg reported Tuesday, citing people with knowledge of the matter.

According to the Bloomberg report, Kalamazoo, Michigan-based Stryker plans to offer a significant premium, likely to be about 30 percent, to Smith & Nephew's current share price. Stryker has a market capitalization of $36.55 billion, while Smith & Nephew has a market capitalization of $16.98 billion.

However, Stryker is reportedly not planning a tax inversion due to the limited tax benefits and political risk.

Several U.S. healthcare companies, are increasingly looking at tax inversions as an option to escape the high rate of corporate taxes in the U.S., which is among the highest in the world, as the U.S. overhauls its healthcare system under the Affordable Care Act. The statutory tax rate in the U.S. is currently 35 percent.

Some of these companies are sitting on huge cash hoards in their overseas subsidiaries and would be heavily taxed if they repatriated these funds to the U.S. However, U.S. lawmakers are now targeting legislation aimed at curbing U.S. companies from doing inversions.

The Financial Times had reported in late May that Stryker was preparing to make an offer to acquire Smith & Nephew. Stryker later denied that report, saying it does not intend to make an offer for the company.

In late June, Stryker agreed to acquire substantially all the assets of privately-held Small Bone Innovations, Inc., including an ankle replacement system, for up to $375 million in cash. Stryker noted that the acquisition of these assets will enable it to bolster its orthopedic portfolio.

SYK closed Tuesday's trading at $96.61, up $1.62 or 1.71 percent on a volume of 3.60 million shares.

SNN closed Tuesday's trading at $38.04, up $3.26 or 9.37 percent on a volume of 3.94 million shares. In after-hours, the stock declined $0.03 or 0.08 percent to $38.01.

Quelle: dpa-AFX

[1435905]

Kleines Update zu Stryker:

Das Unternehmen erhöht die Dividende


Major orthopedic device manufacturer, Stryker Corp., recently hiked its quarterly dividend by 13% to 34.5 cents per share from 30.5 cents. This lifts the annual dividend to $1.38 per share from the current $1.22 and translates into a dividend yield of approximately 1.5%.

The raised quarterly dividend is payable on Jan 30, 2014, to shareholders of record as of Dec 31, 2014. Stryker’s previous dividend increase was made in Dec 2013, when it raised the quarterly payout by 15% to 30.5 cents a share from 26.5 cents.

Stryker’s peers St. Jude Medical and Medtronic also pay regular dividends to its shareholders. Medtronic raised its quarterly dividend by 9% to 30.5 cents in June, while St. Jude hiked its dividend payout by 8% to 27 cents in Feb 2014. Currently, both Medtronic’s and St. Jude’s dividend yield of 1.7% and 1.6%, respectively, compare favorably with that of Stryker’s.

Nevertheless, we believe that the dividend increase underscores Stryker’s commitment to deliver incremental returns to investors leveraging a solid balance sheet, healthy free cash flow and earnings. Stryker exited the third quarter of 2014 with cash and cash equivalents of $1.36 billion, higher than $1.34 billion as of Dec 31, 2013.

Stryker has been consistently driving earnings over the past several quarters, which has in a way led to the dividend hike. In the third quarter of 2014, the company reported adjusted earnings of $1.15 per share, which grew nearly 10.6% year over year and surpassed the Zacks Consensus Estimate by a penny.

Aggressive share repurchases will also boost earnings as well as shareholders’ value in the near term. Notably, Stryker has over $500 million remaining under its current share repurchase program as of Sep 30, 2014.

We believe that Stryker’s acquisition-driven strategy will enhance its long-term growth prospects by expanding its existing product offerings across all business segments. However, it faces intense competition in the orthopedics industry from the likes of Zimmer Holdings, Johnson & Johnson (JNJ - Analyst Report), Smith & Nephew and Biomet. The mergers between Medtronic and Covidien as well as Zimmer Holdings and Biomet will further intensify competition.

[1435905]

Stryker posts 3Q profit, results beat Wall Street forecasts

Stryker Corp. (SYK) on Thursday reported net income of $57 million in its third quarter.

The Kalamazoo, Michigan-based company said it had profit of 16 cents per share. Earnings, adjusted for pretax expenses and amortization costs, were $1.15 per share.

The results topped Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of $1.14 per share.

The medical device maker posted revenue of $2.39 billion in the period, also surpassing Street forecasts. Analysts expected $2.33 billion, according to Zacks.

Stryker expects full-year earnings in the range of $4.75 to $4.80 per share.

Stryker shares have risen slightly more than 5 percent since the beginning of the year, while the Standard & Poor's 500 index has climbed roughly 1 percent. In the final minutes of trading on Thursday, shares hit $79.20, an increase of 11 percent in the last 12 months.

[1435905]

Stryker Q2 Profit Rises

WASHINGTON (dpa-AFX) - Orthopedics devices maker Stryker Corp. (SYK), Thursday reported a slight increase in profit for the second quarter, after a seven percent growth in revenues were almost erased by lower gross margins and higher operating costs. Earnings for the quarter came in line with analysts' estimates, as did revenues.

Kalamazoo, Michigan-based Stryker's second-quarter profit rose to $215 million from $213 million last year. On a per-share basis, earnings were flat with last year at $0.56.

On an adjusted basis, earnings for the quarter rose to $415 million or $1.08 per share from $406 million to $1.07 per share last year. On average, 29 analysts polled by Thomson Reuters expected earnings of $1.08 per share for the quarter. Analysts' estimates typically exclude special items.

Stryker's sales for the quarter grew 6.8 percent to $2.36 billion from $2.21 billion last year. Analysts expected revenues of $2.35 billion for the quarter. Organic sales were up 5 percent.

Reconstructive products sales grew about 6.5 percent to $1.0 billion, while MedSurg sales increased 8.8 percent to $905 million. Neurotechnology and spine segment sales increased 3.8 percent to $430 million.

Gross margins for the quarter dropped to 65.8 percent from 67.0 percent last year.

Looking forward, the company expects full-year adjusted earnings of $4.75 per share to $4.80 per share and organic sales of 5 to 6 percent. Analysts currently estimate full-year earnings of $4.80 per share.

For the third quarter, the company expects adjusted earnings of $1.12 to $1.16 per share. Analysts currently estimate third-quarter earnings of $1.16 per share.

SYK closed Thursday's trading at $81.71, down $0.58 or 0.70%, on the NYSE.

Copyright RTT News/dpa-AFX

[1435905]

Zitat von moerike8: Heute wieder neues ATH bei 61,5x €. Einer meiner Lieblingsaktien (neben Danaher und Coloplast). Einfach pflegeleicht. Hab sogar eine Meldung für den Kursanstieg gefunden

Stryker Declares a 15% Increase in Quarterly Dividend

Kalamazoo, Michigan - February 12, 2014 - Stryker Corporation (NYSE:SYK) announced that its Board of Directors has increased its dividend 15%, compared to the prior year, by declaring a quarterly dividend of $0.305 per share payable on April 30, 2014, to shareholders of record at the close of business on March 31, 2014.

[moerike8]

Heute wieder neues ATH bei 61,5x €. Einer meiner Lieblingsaktien (neben Danaher und Coloplast). Einfach pflegeleicht. Hab sogar eine Meldung für den Kursanstieg gefunden

Stryker Declares a 15% Increase in Quarterly Dividend

Kalamazoo, Michigan - February 12, 2014 - Stryker Corporation (NYSE:SYK) announced that its Board of Directors has increased its dividend 15%, compared to the prior year, by declaring a quarterly dividend of $0.305 per share payable on April 30, 2014, to shareholders of record at the close of business on March 31, 2014.

[1435905]

Stryker hat sich im letzten Jahr mit einem Plus von 30% sehr ordentlich entwickelt.
Geduld und beharrliches Aussitzen von Kursschwächen wird eben belohnt...

[1435905]

Stryker to Acquire Patient Safety


Stryker Corp. (SYK) agreed to acquire Patient Safety Technologies Inc. (PSTX) for about $86 million, a deal that will boost the medical device maker's offerings of operating room equipment.

Patient Safety does business through its SurgiCount Medical Inc. unit. Its Safety-Sponge System and SurgiCount 360 compliance software help prevent foreign objects from being retained in the body while in the operating room, thereby improving patient safety and reducing health-care costs. The system includes bar-coded surgical sponges and towels, an integrated barcode scanner, and compliance-tracking software. Revenue through the first nine months of the year was $14.9 million.

Sponges are the most common retained object during procedures in operating rooms, with about 2,300 incidents reported a year at an average cost per incident of more than $400,000, Stryker said.

SurgiCount, launched in 2006, has a customer base of more than 300 hospitals. The Safety-Sponge System will become part of Stryker's instruments division.

The deal offers Patient Safety holders $2.22 a share, a 50% premium to Monday's close. The stock, which trades over the counter, is off 19% in the past three months but surged in recent trading to approach the offer price.

The companies said the deal is valued at $120 million, which may include the assumption of debt. A representative from Stryker wasn't immediately available for comment.


The deal is subject to stockholder approval and is expected to close in the first quarter.

Makers of orthopedic products, like Stryker, have been hurt as economic worries led some people to delay surgeries, but they have seen some signs of strengthening in the joint-reconstruction market recently. Stryker also is aiming to recover from a series of problems related to some of its devices that have resulted in some product recalls.

Stryker shares edged up 14 cents to $75.16.


Write to Lauren Pollock at [e-mail]


Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

December 31, 2013 09:55 ET (14:55 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

[apfelburli71]

Stryker steigert Quartalsdividende um 15 % auf 0,305 $

http://www.mydividends.de/content/stryker-hebt-die-dividende

[1435905]

Stryker Corporation (SYK - Analyst Report) reported adjusted earnings per share of 98 cents in the third quarter of 2013, up 1.0% year over year. However, it missed the Zacks Consensus Estimate by a penny. Adjusted EPS included costs associated with the Medical Device Excise Tax amounting to 3 cents per share. Adjusted net income increased 0.8% to $373 million in the quarter.

However, the Mich.-based orthopedic device major’s reported net income plunged more than 70% to $103 million or 27 cents a share from $353 million or 92 cents per share. This is mainly due to the negative impact of the company’s various product recalls such as the Rejuvenate and ABG II modular-neck hip stems and the Neptune Waste Management System.

Stryker’s third-quarter revenues grew 4.8% to $2,151 million, slightly missing the Zacks Consensus Estimate of $2,158 million. Volume and product mix contributed 7.1% to sales growth while acquisitions contributed 0.7%. This was partly neutralized by unfavorable pricing impact and foreign currency exchange translation of 0.9% and 2.0%, respectively.

On an organic basis (excluding the impact of acquisitions), net revenues grew 6.1% at constant exchange rate (CER), reflecting solid growth across all the business segments. Revenues in the U.S. climbed 6.5% to $1,449 million, while international revenues inched up 1.5% to $702 million and improved 7.5% at CER.

Adjusted gross margin in the third quarter was 68.8% versus 68.2% in the prior-year quarter. Management asserts that the company’s 5-year plan to drive greater operational efficiencies has led to the improvement in margin.

Selling, general and administrative (SG&A) expenses spiked 43.6% to $1,136 million, mainly due to product recalls. On an adjusted basis, SG&A was 38.0% of sales compared with 38.2% in the year-ago quarter. This decline was on account of a distributor transition in Asia. Research, development and engineering expenses also grew 19.3% to $136 million due to increased investment in additional R&D projects and innovation activities.

Adjusted operating margin of 22.8% declined 20 basis points (bps) from the prior-year quarter. This was mainly due to the medical device tax, pricing pressure and higher R&D spending, partially offset by operational efficiency and favorable product mix.

Segments Analysis

Revenues from Stryker’s core Reconstructive unit grew 6.5% (9.2% at CER) to $949 million in the third quarter. In terms of constant currency, hip sales climbed 9.3%, while the knee business inched up 2.1%. The trauma and extremities business continues to post strong results, with revenues soaring 20.4% at CER, led by robust sales of Foot & Ankle offerings along with contributions from new products and sales force expansion.

Revenues from Stryker’s MedSurg segment increased 1.5% (2.6% at CER) to $792 million, boosted by the Endoscopy and Sustainability Solutions franchises. Within MedSurg, Instrument sales dropped 5.5% in the U.S. due to the Neptune recall and difficult year-over-year comparisons, while the same grew 8.3% overseas. Endoscopy sales were up 8.4% at CER whereas Medical revenues inched up only 0.2% in the quarter under review.


Stryker’s Neurotechnology and Spine segment continued its solid growth streak with revenues increasing 7.7% (up 10.0% at CER) to $410 million. Growth was led by Stryker’s IVS and Neurotechnology businesses. Revenues from the Neurotechnology sub-segment climbed 13.9% at CER, while spinal implant sales improved 5.5% in the quarter.

Financial Health

Stryker ended the third quarter with cash and cash equivalents and marketable securities of $5,138 million, up roughly 19.9% from $4,285 million at the end of 2012. Long-term debt jumped 57.1% to $2,743 million as of Sep 30, 2013, from $1,746 million at the end of 2012.

For the first nine months of 2013, SYK generated solid cash from operations of $1,214 million, 14.4% higher than $1,061 million generated in the first nine months of 2012. The company repurchased shares worth $252 million in the first nine months of 2013 under the company’s share repurchase program. Shares worth approximately $750 million are still available for repurchase.

Outlook

Stryker raised its revenue guidance for 2013 driven by solid sales in the first nine months of the year as well as the prevailing market conditions. Constant currency sales growth guidance, excluding acquisitions, has been raised to the range of 4.5% to 5.5% from the earlier band of 4.0% to 5.5%. The company expects foreign currency to hurt sales by roughly 1.5% to 2.0% in the fourth quarter as well as full year 2013.

However, SYK reiterated its projection for adjusted earnings in the range of $4.20 to $4.26 a share for 2013. The current Zacks Consensus Estimate of $4.23 for 2013 lies within the guided range.

Our Take

Stryker’s share price increased 1.4% to $72.55 on Oct 17, following the announcement of the third quarter results. We are encouraged by the recent stability in SYK’s businesses, especially the core reconstructive business. Moreover, the company’s raised revenue guidance for 2013 reflects management confidence to drive top line growth on the back of a well-diversified product portfolio, increasing footprint in emerging markets and strategic acquisitions.

The company continues to expand its base through acquisitions such as the recently announced decision to takeover MAKO Surgical Corp. (MAKO - Snapshot Report). Although expensive, the acquisition of MAKO’s advanced robotic arm technology is expected to benefit Stryker over the long term.

Despite solid top-line growth reported in the third quarter, we are concerned about Stryker’s increasing expenses, largely related to product recalls, which are hampering the company’s margins. The company needs to address these internal issues to avoid additional expenses. Moreover, the company remains challenged by adverse foreign exchange swings, pricing pressure and a stringent hospital capital budget environment.

Stryker currently carries a Zacks Rank #3 (Hold). While we choose to remain on the sidelines regarding SYK, medical products companies such as Resmed, Inc. (RMD - Snapshot Report) and Bio-Rad Laboratories, Inc. (BIO - Snapshot Report) are expected to do well. Both these stocks carry a Zacks Rank #1 (Strong Buy).